Who
Tara Lynn Kieffer
Chief Product Strategy Officer
Company insider
Files Form 4 as: Chief Product Strategy Officer, Enanta Pharmaceuticals.
In numbers
- Trades disclosed
- 32
- Buys
- 0
- Sells
- 4
- Bought
- $0
- Sold
- $158K
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 7 Dec 2020
- Last trade
- 12 Feb 2026
- Last filed
- 13 Feb 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 12 Feb 2026filed 13 Feb 2026 | ENTA Enanta PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —1,575 at $0.00 | filing |
| 12 Feb 2026filed 13 Feb 2026 | ENTA Enanta PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —4,987 at $0.00 | filing |
| 12 Feb 2026filed 13 Feb 2026 | ENTA Enanta PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $46K3,257 at $14.25 | filing |
| 12 Feb 2026filed 13 Feb 2026 | ENTA Enanta PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —1,575 at $0.00 | filing |
| 12 Feb 2026filed 13 Feb 2026 | ENTA Enanta PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —4,987 at $0.00 | filing |
| 12 Feb 2026filed 13 Feb 2026 | ENTA Enanta PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $46K3,257 at $14.25 | filing |
| 5 Dec 2025filed 5 Dec 2025 | ENTA Enanta PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $30K2,106 at $14.23 | filing |
| 1 Dec 2025filed 3 Dec 2025 | ENTA Enanta PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $11K753 at $14.12 | filing |
| 25 Nov 2025filed 26 Nov 2025 | ENTA Enanta Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 12 Feb 2025filed 14 Feb 2025 | ENTA Enanta PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —7,500 at $0.00 | filing |
| 12 Feb 2025filed 14 Feb 2025 | ENTA Enanta PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $19K3,326 at $5.59 | filing |
| 6 Dec 2024filed 10 Dec 2024 | ENTA Enanta PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $18K2,283 at $8.06 | filing |
| 1 Dec 2024filed 3 Dec 2024 | ENTA Enanta PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $6,476753 at $8.60 | filing |
| 27 Nov 2024filed 27 Nov 2024 | ENTA Enanta Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —81,000 at $0.00 | filing |
| 17 Jun 2024filed 17 Jun 2024 | ENTA Enanta PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $90K7,266 at $12.33 | filing |
| 12 Feb 2024filed 14 Feb 2024 | ENTA Enanta PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —3,320 at $0.00 | filing |
| 12 Feb 2024filed 14 Feb 2024 | ENTA Enanta PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $12K973 at $12.41 | filing |
| 5 Dec 2023filed 6 Dec 2023 | ENTA Enanta PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $20K2,125 at $9.63 | filing |
| 1 Dec 2023filed 5 Dec 2023 | ENTA Enanta PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $7,146753 at $9.49 | filing |
| 22 Nov 2023filed 22 Nov 2023 | ENTA Enanta Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —83,000 at $0.00 | filing |
News
Comparing Amphastar Pharmaceuticals (NASDAQ:AMPH) & Enanta Pharmaceuticals (NASDAQ:ENTA)ENTA · tickerreport.com · 13 Oct 2026Contrasting Enanta Pharmaceuticals (NASDAQ:ENTA) and Scilex (NASDAQ:SCLX)ENTA · themarketsdaily.com · 9 Oct 2026
0 headlines in the last 90 days name Tara Lynn Kieffer; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.